• Entinostat (MS-275, SNDX-275): HDAC1/3 Inhibition and Eme...

  2025-10-30

  Discover how Entinostat (MS-275, SNDX-275), a potent oral HDAC1 and HDAC3 inhibitor, is reshaping functional cancer drug evaluation beyond standard proliferation assays. This article uniquely integrates epigenetic modulation with state-of-the-art in vitro methodologies for advanced oncology research.

• Entinostat (MS-275, SNDX-275): Selective HDAC1/3 Inhibito...

  2025-10-29

  Entinostat (MS-275, SNDX-275) is a potent oral histone deacetylase inhibitor with selective activity against HDAC1 and HDAC3. This article details its quantitative selectivity, mechanism of action, and evidence for its anti-cancer effects, providing machine-readable facts for researchers in cancer epigenetics.

• ABT-263 (Navitoclax): Precision Bcl-2 Family Inhibitor fo...

  2025-10-28

  ABT-263 (Navitoclax) is a potent, orally bioavailable Bcl-2 family inhibitor widely used to study apoptosis mechanisms in cancer biology. This article details its mechanism, validated benchmarks, and protocol integration, providing a factual resource for apoptosis assay and cancer research workflows.

• Entinostat (MS-275): HDAC1/3 Inhibition for Cancer Research

  2025-10-27

  Entinostat (MS-275, SNDX-275) is a potent, selective oral HDAC1 and HDAC3 inhibitor that transforms cancer research workflows through precise epigenetic modulation. This guide details advanced experimental protocols, troubleshooting, and translational insights, empowering scientists to maximize anti-tumor efficacy and data fidelity in vitro and in vivo.

• DiscoveryProbe™ FDA-approved Drug Library: High-Content S...

  2025-10-26

  The DiscoveryProbe™ FDA-approved Drug Library offers a rigorously curated collection of 2,320 clinically approved compounds for high-throughput screening (HTS) and drug repositioning. This FDA-approved bioactive compound library supports reproducible target identification and mechanistic studies, with validated stability and compatibility for modern HTS workflows.

• Beyond the Bottleneck: Mechanism-Driven Strategies for Tr...

  2025-10-25

  Translational researchers are challenged to bridge mechanistic insight with rapid therapeutic advancement. This article unpacks how the DiscoveryProbe™ FDA-approved Drug Library enables high-throughput, mechanism-based discovery—reshaping strategies for target identification, drug repositioning, and pathway elucidation in oncology, neurodegeneration, and beyond. Integrating the latest metabolomics evidence, competitive analysis, and pragmatic guidance, we chart a visionary path for leveraging clinically approved compound libraries to accelerate translational breakthroughs.

• L1023 Anti-Cancer Compound Library: Next-Gen Strategies f...

  2025-10-24

  Delve into the unique advantages of the L1023 Anti-Cancer Compound Library for drug discovery and high-throughput screening of anti-cancer agents. This article explores advanced applications in pathway-targeted oncology and integrates recent breakthroughs in biomarker-driven research.

• Belinostat (PXD101): Mechanistic Insights and Strategic R...

  2025-10-23

  This thought-leadership article provides a comprehensive exploration of Belinostat (PXD101), a potent pan-HDAC inhibitor, within the context of modern translational cancer research. By blending mechanistic understanding, state-of-the-art experimental methods, and strategic perspectives from the competitive landscape, the article offers actionable guidance for researchers. Drawing on pivotal in vitro evaluation frameworks and emphasizing unmet needs in urothelial carcinoma and prostate cancer, it delivers strategic insights for researchers aiming to bridge the gap from bench to bedside.

• L1023 Anti-Cancer Compound Library: Transforming Targeted...

  2025-10-22

  Explore how the L1023 Anti-Cancer Compound Library enables innovative, high-throughput discovery of cell-permeable anti-cancer agents for translational cancer research. This in-depth analysis reveals advanced strategies for integrating pathway-focused compound libraries in precision oncology.

• DOT1L Inhibitor EPZ5676: Precision Tool for Leukemia Rese...

  2025-10-21

  DOT1L inhibitor EPZ-5676 delivers unparalleled selectivity and potency for dissecting epigenetic mechanisms in MLL-rearranged leukemia and beyond. Its robust inhibition of H3K79 methylation and proven cytotoxicity empower researchers to accelerate translational discoveries and optimize workflows for epigenetic cancer therapy.

• GSK126: Selective EZH2/PRC2 Inhibitor for Cancer Epigenetics

  2025-10-20

  GSK126 stands at the forefront of cancer epigenetics research, enabling targeted inhibition of EZH2/PRC2-mediated histone methylation. This article delivers actionable guidance on integrating GSK126 into experimental workflows, troubleshooting solubility and assay optimization, and capitalizing on its unique mechanistic advantages for oncology drug development and immune modulation.

• Panobinostat (LBH589): Broad-Spectrum HDAC Inhibitor for ...

  2025-10-19

  Panobinostat (LBH589) empowers researchers to probe resistance-breaking apoptosis pathways and epigenetic regulation in cancer models. Its nanomolar potency and broad HDAC inhibition profile make it a versatile tool for dissecting cell cycle arrest, caspase activation, and overcoming drug resistance. Integrate this hydroxamic acid-based histone deacetylase inhibitor into your workflow for robust, actionable insights in tumor biology.

• L1023 Anti-Cancer Compound Library: High-Throughput Scree...

  2025-10-18

  The L1023 Anti-Cancer Compound Library delivers a robust, cell-permeable toolkit for high-throughput screening of anti-cancer agents, empowering biomarker-driven discovery and pathway analysis. Its diverse, pathway-targeted compounds and streamlined experimental protocols accelerate target identification and translational research across cancer types.

• Cl-Amidine trifluoroacetate salt: PAD4 Inhibition for Pre...

  2025-10-17

  Explore how Cl-Amidine trifluoroacetate salt, a potent protein arginine deiminase 4 inhibitor, enables next-level research into precision epigenetic regulation and disease modeling. This article uniquely dissects the molecular mechanisms and translational potential of PAD4 inhibition, setting it apart from existing reviews.

• Strategically Targeting Super-Enhancer Hijacking in Early...

  2025-10-16

  This thought-leadership article explores the emerging role of super-enhancer hijacking in early-stage lung adenocarcinoma and the strategic use of SGC-CBP30—a selective CREBBP/EP300 bromodomain inhibitor—to interrogate and disrupt epigenetic vulnerabilities. Integrating recent mechanistic insights, translational research guidance, and a competitive landscape overview, we outline how SGC-CBP30 uniquely empowers researchers to bridge the gap between foundational epigenetics and actionable therapeutic innovation.

16393 records 1/1093 page Next 12345 下5页 Last page